VOR Earnings Date: Nov 12, 2026 (Estimated) — Vor Biopharma Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is VOR's next earnings date?
Vor Biopharma Inc. (VOR) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.84.
How did VOR do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Vor Biopharma Inc. posted EPS of -$0.80 versus the -$0.69 estimate, a miss of 14.3%. Revenue was $0. The stock's 1-day post-earnings move was +0.9%.
How much does VOR stock move after earnings?
VOR beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.0% (up or down) in the day after earnings.
About Vor Biopharma Inc.
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.69 | -0.80 | -14.29% | $0 | ❌ Miss | +0.94% | -1.54% | -0.58% |
| 2026-05-13 | Q1 2026 | -0.78 | -0.73 | +6.41% | $0 | ✅ Beat | -3.40% | -14.21% | -14.45% |
| 2026-03-30 | Q4 2025 | -1.14 | -1.63 | -42.98% | $0 | ❌ Miss | +1.52% | +12.36% | -0.69% |
| 2025-11-13 | Q3 2025 | -3.68 | -3.33 | +9.54% | $0 | ✅ Beat | +2.67% | -29.64% | +38.56% |
| 2025-08-12 | Q2 2025 | -0.58 | -2.19 | -277.59% | $0 | ❌ Miss | +21.69% | +23.49% | +9.34% |
| 2025-03-20 | Q4 2024 | -0.31 | -0.44 | -41.94% | $0 | ❌ Miss | +2.11% | -10.09% | -19.42% |
| 2024-11-07 | Q3 2024 | -0.40 | -0.40 | +0.00% | $0 | ➖ Inline | +14.87% | +7.61% | +24.70% |
| 2024-03-20 | Q4 2023 | -0.50 | -0.39 | +22.00% | $0 | ✅ Beat | +8.89% | +22.78% | -5.00% |
Showing last 8 quarters.